Short-chain fatty acid enemas stimulate plasminogen activator inhibitor-1 after abdominal aortic graft surgery: a double-blinded, placebo-controlled study.
Colonic ischaemia may complicate aortic graft surgery with high mortality from associated colonic necrosis. Loss of the mucosal barrier function due to ischaemia may promote translocation of endotoxins with secondary systemic disseminated coagulation leading to multiple organ failure. Short-chain fatty acids (SCFAs) stimulate the microcirculation in the human rectum. The aim of this study was to investigate whether SCFA enemas influence systemic endotoxinaemia and fibrinolytic activity during and after elective aortic graft surgery for arteriosclerosis. Thirty-two patients were randomized to SCFA or placebo enemas twice daily from the day before surgery to 7 days after. Blood samples for endotoxin, plasminogen activator inhibitor-1 (PAI-1) activity, tissue-type plasminogen activator (t-PA) antigen, and cross-linked fibrin degradation products (XL-FDP) were drawn before, during, and 7 days after surgery. Four patients, two in each treatment group, developed postoperative endotoxinaemia. PAI-1 was significantly higher on days 2 and 4 in SCFA-treated patients, whereas t-PA was comparable Petween the groups. During the postoperative course, a progressive and near-identical XL-FDP increase was found in the two groups. In elective aortic graft surgery for arteriosclerosis, SCFA enemas likely stimulate systemic PAI-1 activity by promoting colonic tissue reperfusion following aortic unclamping. Endotoxinaemia and fibrinolytic shutdown are uncommon findings.
Mortensen
F V
FV
Department of Surgical Gastroenterology L, Aarhus University Hospital, Denmark. f.v.mortensen@dadlnet.dk
Jørgensen
B
B
Christiansen
H M
HM
Sloth-Nielsen
J
J
Wolff
B
B
Hessov
I
I
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000941:Antigens / Q000097:blood / Q000187:drug effects; D001012:Aorta, Abdominal / Q000601:surgery*; D001161:Arteriosclerosis / Q000382:microbiology / Q000601:surgery / Q000628:therapy; D001807:Blood Vessel Prosthesis; D017091:Colitis, Ischemic / Q000517:prevention & control; D003106:Colon / Q000382:microbiology / Q000473:pathology; D004311:Double-Blind Method; D019446:Endotoxemia / Q000188:drug therapy / Q000209:etiology; D004733:Enema / Q000379:methods; D005232:Fatty Acids, Volatile / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000187:drug effects / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D013923:Thromboembolism / Q000517:prevention & control; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000097:blood / Q000187:drug effects / Q000276:immunology; D014946:Wound Infection / Q000150:complications
D000900:Anti-Bacterial Agents; D000941:Antigens; D005232:Fatty Acids, Volatile; D005338:Fibrin Fibrinogen Degradation Products; D010919:Placebos; D017395:Plasminogen Activator Inhibitor 1; D010959:Tissue Plasminogen Activator